Francesco Rodeghiero

List of Publications by Year
in descending order

109 papers	12,541 citations	53794 45 h-index	28297 105 g-index
114 all docs	114 docs citations	114 times ranked	7347 citing authors

#	Article	IF	Citations
1	Immune thrombocytopenia in myeloid and lymphoid clonal disorders: an intriguing association. Haematologica, 2021, 106, 1231-1233.	3.5	2
2	Eltrombopag secondâ€line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission offâ€treatment: results of a phase II, multicentre, prospective study. British Journal of Haematology, 2021, 193, 386-396.	2.5	23
3	PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021032.	1.3	17
4	Thrombosis in immune thrombocytopenia â€" current status and future perspectives. British Journal of Haematology, 2021, 194, 822-834.	2.5	31
5	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. Blood, 2021, 138, 571-583.	1.4	26
6	Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. Journal of Thrombosis and Haemostasis, 2021, 19, 2348-2354.	3.8	7
7	Management of immune thrombocytopenia in women: current standards and special considerations. Expert Review of Hematology, 2020, 13, 175-185.	2.2	20
8	Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60Âyears. Thrombosis Research, 2020, 185, 88-95.	1.7	7
9	Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Expert Review of Hematology, 2020, 13, 1319-1332.	2.2	10
10	Cerebral microbleeds in ITP: alarming or innocent?. Blood, 2020, 136, 2842-2844.	1.4	0
11	Thrombopoietin receptor agonists: ten years later. Haematologica, 2019, 104, 1112-1123.	3.5	219
12	Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (<scp>ITP</scp>) for up to 1Âyear and in those with chronic <scp>ITP</scp> for more than 1Âyear: a subgroup analysis of integrated data from completed romiplostim studies. British Journal of Haematology, 2019, 185, 503-513.	2.5	49
13	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advances, 2019, 3, 3780-3817.	5.2	593
14	Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. Blood, 2019, 134, 1708-1711.	1.4	16
15	A comparative prospective observational study of children and adults with immune thrombocytopenia: 2â€year followâ€up. American Journal of Hematology, 2018, 93, 751-759.	4.1	38
16	A critical appraisal of the evidence for the role of splenectomy in adults and children with <scp>ITP</scp>. British Journal of Haematology, 2018, 181, 183-195.	2.5	58
17	Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers. American Journal of Hematology, 2018, 93, 58-64.	4.1	31
18	Efficacy and Safety of IQYMUNEÂ®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia. Journal of Hematology (Brossard, Quebec), 2018, 7, 87-95.	1.0	3

#	Article	IF	Citations
19	Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Annals of Hematology, 2017, 96, 1421-1434.	1.8	33
20	Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica, 2017, 102, 1342-1351.	3.5	51
21	A hit to current â€œhitâ€•wisdom: A century later, it's time for a change. American Journal of Hematology, 2017, 92, 727-729.	4.1	1
22	ITP and thrombosis: an intriguing association. Blood Advances, 2017, 1, 2280-2280.	5.2	29
23	Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Annals of Hematology, 2016, 95, 1077-1087.	1.8	43
24	Is <scp>ITP</scp> a thrombophilic disorder?. American Journal of Hematology, 2016, 91, 39-45.	4.1	114
25	Healthâ€related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. American Journal of Hematology, 2016, 91, 995-1001.	4.1	53
26	Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome. Annals of Hematology, 2016, 95, 863-870.	1.8	14
27	Thrombotic risk in patients with immune haemolytic anaemia. British Journal of Haematology, 2016, 172, 144-146.	2.5	14
28	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67
29	Treatment of Immune Thrombocytopenia in Adults: The Role of Thrombopoietin-Receptor Agonists. Seminars in Hematology, 2015, 52, 16-24.	3.4	31
30	Von Willebrand disease. Hematology, 2014, 19, 370-371.	1.5	1
31	Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatmentâ€related risk factors. Journal of Thrombosis and Haemostasis, 2014, 12, 1266-1273.	3.8	95
32	Inhibitor development: The last enemy to be defeated in hemophilia A and B. American Journal of Hematology, 2014, 89, 569-570.	4.1	0
33	Autoimmune cytopenias in chronic lymphocytic leukemia. American Journal of Hematology, 2014, 89, 1055-1062.	4.1	93
34	ITP and international guidelines: What do we know, what do we need?. Presse Medicale, 2014, 43, e61-e67.	1.9	39
35	Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood, 2014, 124, 2930-2936.	1.4	268
36	Bâ€cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 32-36.	4.1	36

#	Article	IF	Citations
37	Von Willebrand disease: Pathogenesis and management. Thrombosis Research, 2013, 131, S47-S50.	1.7	13
38	Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 277-282.	4.1	17
39	The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically highâ€risk patients with chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 289-293.	4.1	19
40	Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. Journal of Clinical Oncology, 2013, 31, 1442-1449.	1.6	167
41	Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. American Journal of Hematology, 2013, 88, 955-960.	4.1	14
42	Longâ€term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. European Journal of Haematology, 2013, 91, 423-436.	2.2	90
43	Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood, 2013, 121, 2596-2606.	1.4	179
44	Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica, 2013, 98, 875-880.	3.5	97
45	The expert in hemostasis and thrombosis in the Italian health system: role and requirements for a specific clinical and laboratory expertise. Italian Journal of Medicine, 2013, 7, 71.	0.3	0
46	The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells, Molecules, and Diseases, 2012, 48, 68-75.	1.4	28
47	Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines. Leukemia and Lymphoma, 2012, 53, 2262-2268.	1.3	18
48	TPOâ€receptor agonists in ITP: A clinician's navigation between scylla and charybdis. American Journal of Hematology, 2012, 87, 943-943.	4.1	5
49	Shortâ€and longâ€term risks of splenectomy for benign haematological disorders: should we revisit the indications?. British Journal of Haematology, 2012, 158, 16-29.	2.5	99
50	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. American Journal of Hematology, 2012, 87, 203-204.	4.1	29
51	Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thrombosis and Haemostasis, 2011, 105, 647-654.	3.4	44
52	Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica, 2011, 96, 1831-1837.	3.5	118
53	Advances in the diagnosis and management of type 1 von Willebrand disease. Expert Review of Hematology, 2011, 4, 95-106.	2.2	8
54	Autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia is associated with IgVH status. Haematologica, 2010, 95, 1230-1232.	3.5	33

#	Article	IF	Citations
55	Treatment outcome in a cohort of young patients with polycythemia vera. Internal and Emergency Medicine, 2010, 5, 411-413.	2.0	8
56	Treatment practices in adults with chronic immune thrombocytopenia â€“ a European perspective. European Journal of Haematology, 2010, 84, 160-168.	2.2	23
57	Identical IGHVâ€Dâ€J gene rearrangement may precede the clinical onset of chronic lymphocytic leukemia by several years. American Journal of Hematology, 2010, 85, 868-871.	4.1	6
58	ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. Journal of Thrombosis and Haemostasis, 2010, 8, 2063-2065.	3.8	607
59	The impact of bleeding history, von Willebrand factor and PFAâ€“100‹sup›Â®‹/sup› on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDMâ€1VWD. British Journal of Haematology, 2010, 151, 245-251.	2.5	41
60	Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia. New England Journal of Medicine, 2010, 363, 1889-1899.	27.0	374
61	International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010, 115, 168-186.	1.4	1,802
62	Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. Hematology American Society of Hematology Education Program, 2009, 2009, 113-123.	2.5	17
63	The revival of clinical wisdom: The case of oral anticoagulation management. American Journal of Hematology, 2009, 84, 546-547.	4.1	0
64	Response:Immune thrombocytopenic purpura: terminology and definitions. Blood, 2009, 114, 2004-2004.	1.4	2
65	Thrombosis associated with angiogenesis inhibitors. Best Practice and Research in Clinical Haematology, 2009, 22, 115-128.	1.7	100
66	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009, 113, 2386-2393.	1.4	2,128
67	Immune Thrombocytopenia in Lymphoproliferative Disorders. Hematology/Oncology Clinics of North America, 2009, 23, 1261-1274.	2.2	24
68	How I treat von Willebrand disease. Blood, 2009, 114, 1158-1165.	1.4	79
69	The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood, 2009, 114, 3167-3172.	1.4	216
70	Is splenectomy still the gold standard for the treatment of chronic ITP?. American Journal of Hematology, 2008, 83, 91-91.	4.1	39
71	Flow cytometry in the diagnosis of drugâ€induced thrombocytopenia: Two illustrative cases. American Journal of Hematology, 2008, 83, 326-329.	4.1	5
72	Hemostatic complications of angiogenesis inhibitors in cancer patients. American Journal of Hematology, 2008, 83, 862-870.	4.1	62

#	Article	IF	Citations
73	Firstâ€line therapies for immune thrombocytopenic purpura: reâ€evaluating the need to treat. European Journal of Haematology, 2008, 80, 19-26.	2.2	35
74	Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica, 2008, 93, 98-103.	3.5	59
75	Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica, 2008, 93, 372-380.	3.5	316
76	Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood, 2008, 111, 3998-4003.	1.4	71
77	Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood, 2008, 111, 3531-3539.	1.4	187
78	Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD). Blood, 2008, 111, 4979-4985.	1.4	148
79	Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood, 2008, 111, 1110-1116.	1.4	93
80	A Prospective Evaluation of Bleeding Tendency and Efficacy of Antihemorrhagic Treatments in Patients with Increased Von Willebrand Factor (VWF) Clearance (Von Willebrand Disease Vicenza AND C1130F) Tj ETQq0 0 0 rgBT /Overlock 10	1.4	2
81	Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood, 2007, 109, 1401-1407.	1.4	249
82	Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood, 2007, 109, 112-121.	1.4	364
83	Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia. Clinical Leukemia, 2007, 1, 339-344.	0.2	1
84	Assessing bleeding in von Willebrand disease with bleeding score. Blood Reviews, 2007, 21, 89-97.	5.7	66
85	Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). Journal of Thrombosis and Haemostasis, 2007, 5, 715-721.	3.8	54
86	Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: A critical appraisal from literature analysis. Pediatric Blood and Cancer, 2006, 47, 653-656.	1.5	16
87	Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. American Journal of Hematology, 2006, 81, 426-431.	4.1	59
88	The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. Journal of Thrombosis and Haemostasis, 2005, 3, 2619-2626.	3.8	317
89	Treatment of von Willebrand disease. Seminars in Hematology, 2005, 42, 29-35.	3.4	40
90	The Incidence of Chronic Lymphocytic Leukemia in the General Population.. Blood, 2004, 104, 2809-2809.	1.4	1

#	Article	IF	Citations
91	Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica, 2003, 88, 94-108.	3.5	141
92	Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine. Haematologica, 2003, 88, 1081-7.	3.5	27
93	Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. American Journal of Hematology, 2002, 71, 1-6.	4.1	78
94	Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma. Haematologica, 2002, 87, 1157-64.	3.5	11
95	Congenital von Willebrand disease type 1: definition, phenotypes, clinical and laboratory assessment. Best Practice and Research in Clinical Haematology, 2001, 14, 321-335.	1.7	37
96	Pregnancy in Women with Type 1 von Willebrand Disease Caused by Heterozygosity for von Willebrand Factor Mutation C1130F. Thrombosis and Haemostasis, 2000, 84, 351-352.	3.4	27
97	Inconsistency of Association between Type 1 von Willebrand Disease Phenotype and Genotype in Families Identified in an Epidemiological Investigation. Thrombosis and Haemostasis, 1999, 82, 1065-1070.	3.4	98
98	Homocysteine levels in polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 1999, 105, 551-555.	2.5	39
99	Activated Protein C Resistance and Factor V Leiden Mutation Are Independent Risk Factors for Venous Thromboembolism. Annals of Internal Medicine, 1999, 130, 643.	3.9	199
100	The Epidemiology of Inherited Thrombophilia: the VITA Project. Thrombosis and Haemostasis, 1997, 78, 636-640.	3.4	52
101	The VITA Project: Phenotypic Resistance to Activated Protein C and FV Leiden Mutation in the General Population. Thrombosis and Haemostasis, 1997, 78, 859-863.	3.4	34
102	Prospective Multicenter Study on Subcutaneous Concentrated Desmopressin for Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A. Thrombosis and Haemostasis, 1996, 76, 692-696.	3.4	84
103	Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. British Journal of Haematology, 1995, 89, 147-151.	2.5	43
104	Hydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis. New England Journal of Medicine, 1995, 332, 1132-1137.	27.0	787
105	Current Management of von Willebrand??s Disease. Drugs, 1995, 50, 602-614.	10.9	20
106	Desmopressin-induced thrombocytopenia in type i platelet discordant von willebrand disease. American Journal of Hematology, 1993, 43, 5-9.	4.1	17
107	Replacement Therapy with Virusâ€"Inactivated Plasma Concentrates in von Willebrand Disease. Vox Sanguinis, 1992, 62, 193-199.	1.5	79
108	Von Willebrand Factor Antigen Is Less Sensitive than Ristocetin Cofactor for the Diagnosis of Type I von Willebrand Disease -Results Based on an Epidemiological Investigation. Thrombosis and Haemostasis, 1990, 64, 349-352.	3.4	36

#	Article	IF	Citations
109	Von Willebrand Disease. , 0, , 51-61.		3